[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343303-105":59,"doc-detail-343303-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","organoid-modeling-meets-cancers-of-female-reproductive-tract-review-of-organoid-models-and-open-questions","Organoid Modeling Meets Cancers of Female Reproductive Tract - Review of Organoid Models and Open Questions","","Diseases of the female reproductive system, especially malignant tumors, threaten women’s health worldwide, largely because representative models remain limited. Organoid technology—particularly tumor organoids—enables more faithful disease modeling by recapitulating three-dimensional tumor structure and microenvironment, preserving heterogeneity and patient-specific genetic profiles, and supporting efficient drug screening and personalized medicine. The review summarizes approaches to constructing tumor organoids of the female reproductive tract, highlights applications in cancer research, and outlines limitations and open questions for future development.",{"@graph":69,"@context":119},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/organoid-modeling-meets-cancers-of-female-reproductive-tract-review-of-organoid-models-and-open-questions/343303/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/organoid-modeling-meets-cancers-of-female-reproductive-tract-review-of-organoid-models-and-open-questions/343303.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115],{"name":110,"@type":111,"acceptedAnswer":112},"How are organoids used for drug screening and predicting treatment responses?","Question",{"text":113,"@type":114},"Organoids support high-throughput drug screening and personalized treatment research. Ovarian cancer PDOs have been used to predict responses to chemotherapy regimens such as carboplatin/paclitaxel and to study resistance mechanisms, including HRR-deficient cases.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What open questions remain for improving organoid models of female reproductive tract cancers?",{"text":118,"@type":114},"Key questions include how integrating additional tumor microenvironment components—such as immune cells and fibroblasts—could improve realism. The review also asks how organoid co-culture with microbiota and advanced gene-editing approaches (e.g., CRISPR-Cas9) could further refine modeling of progression and drug resistance, and what challenges limit efficient organoid generation across cancer stages.","https://schema.org",{"og:url":83,"og:type":121,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":123,"canonical":83},"index,follow",{"doc_id":125,"site_id":62},343303,1790195352,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":92,"user_avatar":130,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":136,"language":137,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":67,"update_tm":141,"read_time":36,"preview_page_count":19,"preview_urls":142},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","[www.nature.com/cddiscovery](www.nature.com/cddiscovery)  \nREVIEW ARTICLE OPEN   \nOrganoid modeling meets cancers of female reproductive tract  \nJiao Li 1,2,10, Mengting Zhou 1,3,10, Jun Xie4,10, Jiani Chen5, Mengni Yang 1,3, Changjun Ye6, Shihu Cheng7, Miao Liu 8 ✉, Rui Li 9 ✉ and Ruirong Tan 1 ✉  \n© The Author(s) 2024  \n\n|  | Diseases of the female reproductive system, especially malignant tumors, pose a serious threat to women’s health worldwide. Oneof the key factors limiting research progress in this area is the lack of representative models. Organoid technology, especially tumor organoids, has been increasingly applied in the study of female reproductive system tumors due to their high heterogeneity, close resemblance to the physiological state, easy acquisition and cultivation advantages. They play a signiﬁcant role in understanding the origin and causes of tumors, drug screening, and personalized treatment and more. This article reviews the organoid models for the female reproductive system, focusing on the cancer research advancements. It discusses the methods for constructing tumor organoids of the female reproductive tract and summarizes the limitations of current research. The aim is to offer a reference for future development and application of these organoid models, contributing to the advancement of anti-tumor drugs and |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| treatment strategies for female reproductive tract cancer patients. |  |  |\n|  | Cell Death Discovery (2024)10:410; [https://doi.org/10.1038/s41420-024-02186-x](https://doi.org/10.1038/s41420-024-02186-x) |  |\n|  |  |  |\n\nFACTS  \n● Stem cell-derived organoids function both as models for disease and as tools for studying tissue regeneration. In contrast to 2D cell lines and expensive, time-consuming animal models, organoids more accurately replicate the threedimensional structure and microenvironment of tumors, preserve tumor heterogeneity and patient-speciﬁc genetic proﬁles, and are well-suited for high-throughput drug screening and personalized medicine research.  \n● Patient-derived organoids (PDOs) often retain key cellular subgroups from the original tumor, preserving its heterogeneity. This characteristic is crucial for disease modeling, as seen in fallopian tube organoids, which provide insights into the progression of ovarian cancer.  \n● Organoids are pivotal in high-throughput drug screening and personalized treatment approaches. Ovarian cancer PDOs, for example, have been used to predict patient responses to chemotherapy, such as carboplatin/paclitaxel, and to investigate resistance mechanisms, particularly in HRR-deﬁcient cases.  \n● Organoids co-cultured with immune cells, such as tumorinﬁltrating lymphocytes (TILs), offer a valuable platform for studying immune responses in cancer. In cervical cancer, organoid co-culture with immune cells has shown potential in identifying therapeutic targets and developing immunotherapy strategies.  \n● Emerging technologies, including CRISPR-Cas9 gene editing, organ-on-a-chip systems, and advanced ECM-based scaffolds, are enhancing the precision of organoid models. These innovations facilitate better replication of the tumor microenvironment, supporting research in gynecological cancers such as cervical, endometrial, and ovarian cancer.  \nOPEN QUESTIONS  \n● How can integrating more components of the tumor microenvironment, such as immune cells and ﬁbroblasts, improve the replication of real tumor conditions in organoid models of female reproductive tract cancers?  \n● What new insights can be gained by co-culturing organoids with microbiota, particularly for understanding endometrial and ovarian cancer development? How can geneediting technologies like CRISPR-Cas9 further reﬁne organoid models for studying cancer progression and drug resistance?  \n● What are the key challenges in improving the efﬁciency of generating organoids from different stages of","cbCaihRNgkwyld8L","https://ap.wps.com/l/cbCaihRNgkwyld8L","pdf",2461271,16,"English","# Introduction\n# Facts\n## Stem cell-derived organoids as disease models\n## Patient-derived organoids and tumor heterogeneity\n## Drug screening and personalized treatment\n## Immune-cell co-culture and immunotherapy platforms\n## Emerging technologies for improved model fidelity\n# Open Questions","[{\"question\":\"How are organoids used for drug screening and predicting treatment responses?\",\"answer\":\"Organoids support high-throughput drug screening and personalized treatment research. Ovarian cancer PDOs have been used to predict responses to chemotherapy regimens such as carboplatin/paclitaxel and to study resistance mechanisms, including HRR-deficient cases.\"},{\"question\":\"What open questions remain for improving organoid models of female reproductive tract cancers?\",\"answer\":\"Key questions include how integrating additional tumor microenvironment components—such as immune cells and fibroblasts—could improve realism. The review also asks how organoid co-culture with microbiota and advanced gene-editing approaches (e.g., CRISPR-Cas9) could further refine modeling of progression and drug resistance, and what challenges limit efficient organoid generation across cancer stages.\"}]","Organoid Modeling Meets Cancers of Female Reproductive Tract - Review of Organoid Models and Open Questions | PDF",1790050669,[143,147,151,155],{"page_no":8,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ee6a0084f4aeb908cb5fc439dc747a4.webp",983,1305,{"page_no":14,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52e728dd69260821716452fe3d7accb2.webp",982,1304,{"page_no":81,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10e67ac2329863c6fe128796772ba555.webp",981,1303,{"page_no":19,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6243ece7edd3272c994374e61ee62d5.webp",980,1301]